Skip to main content
    T

    Theriva Biologics Inc. (TOVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE MKT

    $0.22
    +0.01 (+3.05%)

    Market Cap: $9.63M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(25/39)
    Avg Surprise
    -36.03%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.06
    Range$-0.06 - $-0.06
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.05-20.0%
    60d ago$-0.05-20.0%
    30d ago$-0.05-20.0%
    7d ago$-0.05-20.0%
    Current$-0.06
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    1 analysts
    Revenue Consensus
    $300000
    Range$300000 - $300000
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.09---
    Sep 26EST
    		-$-0.06---
    Jun 26
    Reported Aug 11
    		$-0.07$-0.05-40.00%Miss+96.4%
    Mar 26
    Reported May 5
    		$-0.05$-0.05+0.00%Beat+96.8%
    Dec 25
    Reported Mar 12
    		$-0.10N/A+73.46%Beat+99.1%
    Sep 25
    Reported Nov 12
    		$-0.45$-0.38-18.42%Miss+93.4%
    Jun 25
    Reported Aug 11
    		$-1.93$-0.47-310.64%Miss+82.0%
    Mar 25
    Reported May 14
    		$-1.55$-1.56+0.64%Beat+79.3%
    Dec 24
    Reported Mar 6
    		$-11.49$-7.22-59.14%Miss-3279.4%
    Sep 24
    Reported Nov 12
    		$-6.81$-5.25-29.71%Miss-43.4%
    Jun 24
    Reported Aug 13
    		$-10.75$-4.75-126.32%Miss-26.5%
    Mar 24
    Reported May 7
    		$-7.50$-8.50+11.76%Beat+0.0%
    Dec 23
    Reported Mar 25
    		$-0.34$-0.41+17.07%Beat-3.0%
    Sep 23
    Reported Nov 13
    		$-4.75$-8.50+44.12%Beat+42.4%
    Jun 23
    Reported Aug 8
    		$-8.50$-8.50+0.00%Beat-9.7%
    Mar 23
    Reported May 11
    		$-7.50$-8.00+6.25%Beat-2400.0%
    Dec 22
    Reported Mar 30
    		$-0.33$-0.33+0.00%Beat+96.7%
    Sep 22
    Reported Nov 10
    		$-8.25$-11.25+26.67%Beat-65.0%
    Jun 22
    Reported Aug 11
    		$-7.75$-7.50-3.33%Miss-55.0%
    Mar 22
    Reported May 16
    		$-0.30$-0.30+0.00%Beat+99.1%
    Dec 21
    Reported Mar 16
    		$-10.00$-5.00-100.00%Miss-614.3%
    Sep 21
    Reported Nov 3
    		$-5.00$-5.00+0.00%Beat+85.7%
    Jun 21
    Reported Aug 5
    		$-5.00$-5.00+0.00%Beat+88.9%
    Mar 21
    Reported May 5
    		$-32.50$-5.00-550.00%Miss-1811.8%
    Dec 20
    Reported Mar 4
    		$-1.40$-0.80-75.00%Miss+97.1%
    Sep 20
    Reported Nov 10
    		$-35.00$-40.00+12.50%Beat+54.8%
    Jun 20
    Reported Aug 6
    		$-45.00$-35.00-28.57%Miss-1945.5%
    Mar 20
    Reported May 5
    		$-1.70$-2.70+37.04%Beat+22.7%
    Dec 19
    Reported Feb 20
    		$-47.50$-57.50+17.39%Beat+85.7%
    Sep 19
    Reported Nov 4
    		$-77.50$-57.50-34.78%Miss+66.7%
    Jun 19
    Reported Aug 8
    		$-2.20$-2.30+4.35%Beat+99.2%
    Mar 19
    Reported May 8
    		$-2.20$-2.30+4.35%Beat+98.7%
    Dec 18
    Reported Feb 27
    		$-332.50$-48.75-582.05%Miss-4850.0%
    Sep 18
    Reported Nov 8
    		$-232.50N/A+55.71%Beat+81.0%
    Jun 18
    Reported Aug 8
    		$-262.50$-350.00+25.00%Beat+0.0%
    Mar 18
    Reported May 8
    		$-175.00N/A+60.00%Beat+0.0%
    Dec 17
    Reported Feb 22
    		$7.00N/A+142.87%Beat+200.0%
    Sep 17
    Reported Nov 1
    		$-1225.00$-437.50-180.00%Miss-
    Jun 17
    Reported Aug 3
    		$-262.50$-495.83+47.06%Beat-
    Mar 17
    Reported May 4
    		$-175.00N/A+72.73%Beat-
    Dec 16
    Reported Mar 2
    		$-7.00N/A+73.68%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.32EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-4022.00%
    ROE-101.90%ROIC-52.69%
    Financial Health
    Debt/Equity0.47xInterest CoverageN/A
    Current Ratio1.13xQuick Ratio1.13x
    Trading Statistics
    Beta1.19Avg Volume498.75K
    52-Week High$0.4952-Week Low$0.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.22
    SMA 20$0.22
    SMA 50$0.23
    SMA 200$0.24
    EMA 10$0.22
    EMA 20$0.22
    EMA 50$0.23
    EMA 200$0.29

    MACD

    Line: -0.01Signal: -0.00Hist: -0.00

    ADX

    ADX: 14.2+DI: 13.1-DI: 17.7

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$0.24

    Bollinger Bands

    Upper Band$0.24
    Lower Band$0.21
    %B Position1370%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    43.6

    Momentum Oscillators

    Stoch %K11.3
    Stoch %D15.1
    Williams %R-82.0
    ROC (10d)-3.9%
    Momentum-0.01
    CCI (20d)-119.4
    MFI (14d)54.6

    Volatility Measures

    ATR (14d)$0.01(6.7%)
    StdDev (20d)0.01
    Hist Vol48.4%(High)

    Volume Flow

    VWAP$0.22
    OBV2.4B
    AD Line-1.6B
    CMF (20d)-0.526

    Volume Metrics

    Avg Vol (20d)497.7K
    Vol Ratio0.7x
    VWMA (20d)$0.22

    Pivot Points

    R3$0.23
    R2$0.23
    R1$0.22
    Pivot Point$0.21
    S1$0.21
    S2$0.20
    S3$0.19

    Advanced Oscillators

    TSI-12.87
    Ultimate Osc28.6
    KST-67.13

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$300,000$0$0$0$0$154,000$0$0$0$758,000$0
    Cost of Revenue$0$0$27,000$0$0$0$27,000$0$0$0$39,000$0
    Gross Profit$0$300,000$-27,000$0$0$0$-27,000$0$0$0$-39,000$0
    Operating Expenses$3.29M$2.43M$2.06M$4.44M$13.13M$4.42M$4.58M$7.89M$8.49M$5.39M$6.21M$4.22M
    R&D$1.27M$355,000$1.13M$2.55M$1.95M$2.97M$2.88M$2.73M$2.95M$3.46M$4.20M$4.01M
    SG&A$2.03M$2.07M$930,000$1.89M$11.18M$1.45M$1.69M$2.30M$1.47M$1.93M$2.02M$212,000
    Operating Income$-3,295,000$-2,127,000$-2,062,000$-4,440,000$-13,132,000$-4,417,000$-4,579,000$-7,887,000$-8,488,000$-5,392,000$-6,215,000$-4,218,000
    Interest Income$79,000$82,000$72,000$65,000$54,000$96,000$138,000$158,000$173,000$228,000$312,000$382,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-3,217,000$-2,044,000$-1,996,000$-4,361,000$-13,058,000$-4,324,000$-4,446,000$-7,726,000$-8,316,000$-5,165,000$-5,908,000$-3,830,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$-424,000$-527,000
    Net Income$-3,217,000$-2,044,000$-1,996,000$-4,361,000$-13,058,000$-4,324,000$-4,446,000$-7,726,000$-8,316,000$-5,165,000$-5,484,000$-3,303,000
    EBITDA$-3,272,000$-2,102,000$-2,041,000$-4,398,000$-13,085,000$-4,394,000$-4,557,000$-7,851,000$-8,451,000$-5,354,000$-6,181,000$-4,180,000
    EBIT$-3,296,000$-2,126,000$-2,068,000$-4,426,000$-13,112,000$-4,420,000$-4,584,000$-7,884,000$-8,489,000$-5,393,000$-6,220,000$-4,212,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TOVX

    News

    Form PRE 14A Theriva Biologics Inc For: 9 October By Investing.com

    Investing.com reported on October 9, 2026, about a Form PRE 14A filing by Theriva Biologics Inc. The article, originating from Reuters...

    Investing.com Nigeria•10/9/26•Somewhat-Bearish

    Form PRE 14A Theriva Biologics Inc For: 9 October By Investing.com

    This article announces the filing of Form PRE 14A by Theriva Biologics Inc. on October 9. The content primarily consists of navigation links, market data, and unrelated news articles...

    Investing.com Canada•10/9/26•Neutral

    Adding a virus to chemotherapy was linked to improved survival in a pancreatic cancer trial

    Theriva Biologics announced that results from its VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic cancer have been published in Nature Medicine. The trial showed that combining VCN-01...

    Stock Titan•9/30/26•Bullish

    Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

    Theriva™ Biologics announced the publication of detailed results from its VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic cancer in Nature Medicine. The study showed improved overall survival...

    Yahoo! Finance Canada•9/30/26•Bullish

    Theriva publishes VCN-01 pancreatic cancer trial data in journal By Investing.com

    Theriva Biologics has announced the publication of results from its VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic cancer patients in Nature Medicine. The study demonstrated improved overall survival...

    Investing.com Canada•9/30/26•Bullish

    TOVX Valuation and Fair Value

    P/E
    -0.3x
    P/B
    0.8x
    See GNG's fair value

    TOVX Profitability: Margins, ROIC and FCF

    Operating margin
    -4022.0%
    Net margin
    0.0%
    ROIC
    -52.7%
    ROE
    -101.9%
    FCF margin
    -4253.7%

    TOVX Competitors

    CompanyTicker
    Neuroone Medical Technologies CorpNMTC
    VistaGen Therapeutics IncVTGN
    Karyopharm Therapeutics IncKPTI
    Check Cap LtdCHEK
    Bullfrog AI Holdings, Inc. Common StockBFRG
    Chemomab Therapeutics Ltd DRCCMMB
    Lantern Pharma IncLTRN
    MetaVia Inc.MTVA

    Sector: Healthcare

    TOVX Bull Case vs Bear Case

    Bear case

    • TOVX beat EPS estimates in 25.0% of its last 8 reported quarters.

    TOVX Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -48.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.06
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About TOVX

    Does TOVX pay dividends?

    Theriva Biologics Inc. (TOVX) does not currently pay a regular dividend.

    What is TOVX's market cap?

    Theriva Biologics Inc. (TOVX) has a market capitalization of $9.63M with a current stock price of $0.22.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In